TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34406549

Group type: EXPERIMENTAL
Intervention: Mental simulation of future waterpipe tobacco smoking (WTS)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Positive or no valence mental simulation of WTS
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Negative mental simulation of WTS
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Mental simulation of WTS
Number of subjects: 1000
Study: 33879902

Group type: EXPERIMENTAL
Intervention: Prognostic nomogram model based on immune inflammation-related markers
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Prognostic nomogram model based on peripheral blood parameters
Number of subjects: 200

Group type: COMPARATOR
Intervention: Peripheral blood parameters
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-muscle-invasive ureteral urothelial carcinoma
Number of subjects: 200

Group type: COMPARATOR
Intervention: Muscle-invasive ureteral urothelial carcinoma
Number of subjects: 200
Study: 35667164

Group type: EXPERIMENTAL
Intervention: Early palliative care consultation within 72 hours of hospitalization
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard intensive care
Number of subjects: 22
Study: 32131070

Group type: EXPERIMENTAL
Intervention: Suicide prevention nursing competency program (120 minutes, twice a week for 3 weeks)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Suicide prevention nursing competency program
Number of subjects: 66
Study: 35272560

Group type: EXPERIMENTAL
Intervention: Scleral buckle
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combined scleral buckle and vitrectomy
Number of subjects: 16
Study: 32769757

Group type: EXPERIMENTAL
Intervention: Fezolinetant 15, 30, 60, or 90 mg BID or 30, 60, or 120 mg QD
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Fezolinetant
Number of subjects: 356
Study: 32221809

Group type: EXPERIMENTAL
Intervention: Percutaneous needle aspiration (PNA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Percutaneous catheter drainage (PCD)
Number of subjects: 100
Study: 35927616

Group type: EXPERIMENTAL
Intervention: Specialized outpatient follow-up for one year post-discharge
Number of subjects: 173

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 173
Study: 32407654

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg‐1)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 19
Study: 35029612

Group type: EXPERIMENTAL
Intervention: Gluten Friendly™ bread (3 g)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Gluten Friendly™ bread (6 g)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Gluten Friendly™ bread (0 g)
Number of subjects: 48
Study: 33818140

Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 943

Group type: COMPARATOR
Intervention: Apalutamide
Number of subjects: 943

Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 943
Study: 32075507

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (bolus 1.5 mg kg−1 followed by 1.5 mg kg−1 h−1 for 3 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxaliplatin without lidocaine
Number of subjects: 0
Study: 36115968

Group type: EXPERIMENTAL
Intervention: 2 L PEG + LB
Number of subjects: 140

Group type: COMPARATOR
Intervention: 4 L PEG
Number of subjects: 140
Study: 33887208

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 sclamp vaccine at 5 μg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 sclamp vaccine at 15 μg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 sclamp vaccine at 45 μg (two doses)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 sclamp vaccine at 45 μg (single dose)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Two doses of sclamp vaccine at any concentration
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 sclamp vaccine at any dose
Number of subjects: 120
Study: 33169704

Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) insufflation
Number of subjects: 204

Group type: COMPARATOR
Intervention: Room air (RA) insufflation
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: CO2 insufflation in patients with inflammatory bowel disease (IBD)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Other contributing factors to pain sensation
Number of subjects: 204
Study: 36472683

Group type: EXPERIMENTAL
Intervention: Immediate loading by housings (group A)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Delayed loading (group B)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Mandibular MIs
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Maxillary MIs
Number of subjects: 79
Study: 34330881

Group type: EXPERIMENTAL
Intervention: Postdischarge nurse phone call
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard hospital discharge processes
Number of subjects: 0
Study: 35879528

Group type: EXPERIMENTAL
Intervention: Palaeolithic diet
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control low-fat diet
Number of subjects: 70
Study: 34851202

Group type: EXPERIMENTAL
Intervention: TELECARE (remote bio-parameters telemonitoring system)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: TELECARE
Number of subjects: 510
Study: 35659655

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) applied on days 0, 3, 7, 14, and every 2 weeks thereafter using a Diode laser with a wavelength of 980 nm.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) applied every 3 weeks using a Diode laser with a wavelength of 980 nm.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no PBM treatment).
Number of subjects: 20
Study: 32570678

Group type: EXPERIMENTAL
Intervention: Artificial intelligence conversational agent technologies and behavioral activation therapy techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35184228

Group type: EXPERIMENTAL
Intervention: JUUL2 prototype 18 mg/mL nicotine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: JUUL2 prototype 40 mg/mL
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: JUUL
Number of subjects: 40

Group type: COMPARATOR
Intervention: IQOS 18 mg/g
Number of subjects: 40

Group type: COMPARATOR
Intervention: Combustible cigarettes
Number of subjects: 40

Group type: COMPARATOR
Intervention: JUUL 59 mg/mL
Number of subjects: 40
Study: 35811184

Group type: EXPERIMENTAL
Intervention: School-based fruit and vegetable promotion program for 24 weeks
Number of subjects: 6
Study: 32446298

Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment
Number of subjects: 3570

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3570
Study: 36164960

Group type: EXPERIMENTAL
Intervention: Masked condition (smiling)
Number of subjects: 950

Group type: COMPARATOR
Intervention: Unmasked condition (smiling)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: In-person evaluation
Number of subjects: 950

Group type: COMPARATOR
Intervention: Online evaluation
Number of subjects: 950
Study: 34006080

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bone graft material
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bone graft material and platelet-rich fibrin
Number of subjects: 16
Study: 34081223

Group type: EXPERIMENTAL
Intervention: Physiology-guided PCI using Fractional Flow Reserve (FFR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-hyperemic instantaneous wave-free ratio-guided revascularization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative flow reserve ratio assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary physiological assessment
Number of subjects: 0
Study: 32210365

Group type: EXPERIMENTAL
Intervention: Vx-001
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 33370616

Group type: EXPERIMENTAL
Intervention: Water First intervention (installation of lead-free water stations, provision of cups/reusable water bottles, 6-month healthy beverage education campaign)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Water First intervention
Number of subjects: 26
Study: 32545038

Group type: EXPERIMENTAL
Intervention: Pepino extract 250mg/kg BW
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pepino extract 500mg/kg BW
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 34125321

Group type: EXPERIMENTAL
Intervention: SRP with ERL and NDL
Number of subjects: 32

Group type: COMPARATOR
Intervention: SRP with ultrasonic equipment and manual instruments (Control)
Number of subjects: 32
Study: 36174917

Group type: EXPERIMENTAL
Intervention: Bundle of care
Number of subjects: 260

Group type: COMPARATOR
Intervention: Ordinary nursing care (control group)
Number of subjects: 260
Study: 33184328

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (100,000 IU single dose)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 35735110

Group type: EXPERIMENTAL
Intervention: Grade 4 IVHVD
Number of subjects: 32

Group type: COMPARATOR
Intervention: Grade 3 IVHVD
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Each extra vision impairment
Number of subjects: 32
Study: 32006493

Group type: EXPERIMENTAL
Intervention: Reporting of confidence intervals (CIs) in RCTs
Number of subjects: 102

Group type: COMPARATOR
Intervention: Anesthesia/facial pain studies
Number of subjects: 102

Group type: COMPARATOR
Intervention: Craniomaxillofacial deformities studies
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Overall reporting of P values
Number of subjects: 102
Study: 34008107

Group type: EXPERIMENTAL
Intervention: End-to-side anastomosis
Number of subjects: 130
Study: 34130339

Group type: EXPERIMENTAL
Intervention: Aspirin for preventing preeclampsia and small-for-gestational-age births in high-risk women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin for secondary prevention of cardiovascular disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin for recurrent venous thromboembolism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twice-daily dosing regimen or evening intake of aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enteric-coated formulations of aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shorter aspirin duration strategies after percutaneous coronary interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin for reducing the risk of colorectal cancer and other types of cancer
Number of subjects: 0
Study: 32161164

Group type: EXPERIMENTAL
Intervention: MAP 100‐110 mm Hg
Number of subjects: 8

Group type: COMPARATOR
Intervention: MAP 60‐80 mm Hg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: EtCO2 38‐40 mm Hg
Number of subjects: 8

Group type: COMPARATOR
Intervention: EtCO2 24‐26 mm Hg
Number of subjects: 8
Study: 35361735

Group type: EXPERIMENTAL
Intervention: Single Isometric Bench Press (SIBP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Multiple Isometric Bench Press (MIBP)
Number of subjects: 16
Study: 33989641

Group type: EXPERIMENTAL
Intervention: IV ibuprofen
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: IV paracetamol
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 75
Study: 33006195

Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) TENS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sub-sensory Low-Intensity (LI) TENS
Number of subjects: 10
Study: 33779383

Group type: EXPERIMENTAL
Intervention: High doses of THC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized clinical trials of psilocybin
Number of subjects: 0
Study: 33271847

Group type: EXPERIMENTAL
Intervention: Access to desktop/laptops
Number of subjects: 2039

Group type: EXPERIMENTAL
Intervention: Use of mobile internet
Number of subjects: 2039

Group type: EXPERIMENTAL
Intervention: Experience of social media
Number of subjects: 2039

Group type: EXPERIMENTAL
Intervention: Link between social media experience and negative outcomes
Number of subjects: 2039

Group type: EXPERIMENTAL
Intervention: Access improvements
Number of subjects: 2039

Group type: EXPERIMENTAL
Intervention: Preventive measures for harmful media usage
Number of subjects: 2039
Study: 35038699

Group type: EXPERIMENTAL
Intervention: Continuous blood pressure monitoring (Finapres) for 5 min in supine position and 3 min standing or sitting when unable to stand.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Interventions to warm hands and adjusting cuff pressure sizes were attempted if no signal was obtained.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 37
Study: 32601670

Group type: EXPERIMENTAL
Intervention: Active Brains program (walking using time goals)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Active Brains-Fitbit program (walking reinforced by a Fitbit)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Educational control (not detailed in the abstract)
Number of subjects: 23
Study: 32516959

Group type: EXPERIMENTAL
Intervention: Betaine supplementation (BET; N = 14)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo group (PLA; N = 15)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Betaine supplementation (BET)
Number of subjects: 29
Study: 36417058

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 561
Study: 33511817

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (3 sessions per week, 30 to 45 minutes each session, 50-70% maximum heart rate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 30
Study: 32485433

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) to the subgenual anterior cingulate cortex (sgACC) or nucleus accumbens (NAc)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 7
Study: 35478399

Group type: EXPERIMENTAL
Intervention: Drugs with orphan drug designation
Number of subjects: 130
Study: 34886880

Group type: EXPERIMENTAL
Intervention: ragweed SLIT-tablet (12 Amb a 1-U)
Number of subjects: 246

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 246
Study: 36273186

Group type: EXPERIMENTAL
Intervention: Intensity-modulated proton therapy (IMPT)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 232
Study: 33853878

Group type: EXPERIMENTAL
Intervention: Discontinued oxytocin stimulation
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Continued oxytocin stimulation
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Discontinued oxytocin stimulation in parous women with no previous caesarean section
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Continued oxytocin stimulation in parous women with no previous caesarean section
Number of subjects: 1200
Study: 34533477

Group type: EXPERIMENTAL
Intervention: K-wire fixation and above-elbow cast
Number of subjects: 128

Group type: COMPARATOR
Intervention: Above-elbow cast
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Malunion group (casting)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Acceptable alignment group (no malunion)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Factors associated with limited forearm rotation
Number of subjects: 128
Study: 32032428

Group type: EXPERIMENTAL
Intervention: 110 µm cap thickness
Number of subjects: 100

Group type: COMPARATOR
Intervention: 140 µm cap thickness
Number of subjects: 100
Study: 35307068

Group type: EXPERIMENTAL
Intervention: Dachengqi decoction combined with octreotide
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional western medicine (octreotide + symptomatic treatment)
Number of subjects: 64
Study: 32115639

Group type: EXPERIMENTAL
Intervention: Dual-marker technique (TiO2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Double n-alkane ratio technique (ALK)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pulse dose technique (Yttrium)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fresh-cut perennial ryegrass (Lolium perenne L.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fresh-cut plantain (Plantago lanceolata)
Number of subjects: 8
Study: 33477158

Group type: EXPERIMENTAL
Intervention: Argatroban injection 60 mg intravenously for 2 days, then 10 mg bid for 5 days (total 7 days)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Routine treatment (control group)
Number of subjects: 344
Study: 32981799

Group type: EXPERIMENTAL
Intervention: One-anastomosis gastric bypass (OAGB)
Number of subjects: 50
Study: 32425024

Group type: EXPERIMENTAL
Intervention: Ultrasonic technique for implant site preparation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional drilling technique
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups (Ultrasonic and Conventional)
Number of subjects: 49
Study: 34986027

Group type: EXPERIMENTAL
Intervention: Exergaming session (EGS) in the ExerCube (25 minutes)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Moderate-intensity endurance exercise (MIEE) session on a treadmill (35 minutes, 65%-70% of maximal heart rate)
Number of subjects: 28
Study: 33334633

Group type: EXPERIMENTAL
Intervention: Online training module for shared decision making
Number of subjects: 187

Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 187
Study: 32430457

Group type: EXPERIMENTAL
Intervention: Electronic software 'prompt' with health care professional training
Number of subjects: 2721

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 2721
Study: 36322033

Group type: EXPERIMENTAL
Intervention: Fascia iliaca block with general anaesthesia (GA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Subarachnoid anaesthesia with morphine and bupivacaine (SAB)
Number of subjects: 28
Study: 34432383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 33544911

Group type: EXPERIMENTAL
Intervention: High-quality reports
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Moderate-quality reports
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-quality reports
Number of subjects: 50

Group type: COMPARATOR
Intervention: Reports from Europe
Number of subjects: 50

Group type: COMPARATOR
Intervention: Reports published in impact factor journals
Number of subjects: 50

Group type: COMPARATOR
Intervention: Reports adhering to CONSORT guidelines
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clinical trials with protocols registered a priori
Number of subjects: 50
Study: 32446832

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 0.5% QD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 1% QD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 0.5% BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 1% BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle QD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle BID
Number of subjects: 0
Study: 35359909

Group type: EXPERIMENTAL
Intervention: Integrative neuromuscular training (6 months of supervised physical exercise and home-based exercise)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Usual care + unsupervised written home-based training program (active control)
Number of subjects: 127
Study: 33683083

Group type: EXPERIMENTAL
Intervention: Halobetasol Propionate 0.01% lotion
Number of subjects: 119

Group type: COMPARATOR
Intervention: Vehicle lotion
Number of subjects: 119
Study: 32482645

Group type: EXPERIMENTAL
Intervention: csDMARD tapering first
Number of subjects: 189

Group type: COMPARATOR
Intervention: TNF-inhibitor tapering first
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 189
Study: 35915460

Group type: EXPERIMENTAL
Intervention: PhunkyFoods programme (n = 210)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Usual school curriculum (n = 210)
Number of subjects: 420
Study: 33642167

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Beta-blockers in patients with LVEF ≤40%
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Beta-blockers in patients with LVEF >40%
Number of subjects: 972
Study: 32933119

Group type: EXPERIMENTAL
Intervention: Person-centered nursing intervention program for frailty (PNIF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (lectures about frailty prevention)
Number of subjects: 40
Study: 35257622

Group type: EXPERIMENTAL
Intervention: Caffeine (200mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32089099

Group type: EXPERIMENTAL
Intervention: Cerebellar stroke group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Hemispheric stroke group
Number of subjects: 33
Study: 35833413

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy + surgery (RT+S)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Surgery alone (S)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Preoperative radiotherapy (RT)
Number of subjects: 321
Study: 34518098

Group type: EXPERIMENTAL
Intervention: tDCS over M1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: tDCS over S1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: tDCS over DLPFC
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 80
Study: 34799418

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus lenvatinib
Number of subjects: 875

Group type: COMPARATOR
Intervention: Paclitaxel plus carboplatin
Number of subjects: 875
Study: 33743385

Group type: EXPERIMENTAL
Intervention: MHP+TAU
Number of subjects: 124

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 124
Study: 34425247

Group type: EXPERIMENTAL
Intervention: Memory-reframing intervention
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 33606965

Group type: EXPERIMENTAL
Intervention: Compression garment stockings (CGS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No compression garment stockings (control)
Number of subjects: 20
Study: 32166534

Group type: EXPERIMENTAL
Intervention: Desmopressin (dDAVP) administered intravenously in doses from 0.25 to 2.0 µg/kg over two consecutive days.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Desmopressin (dDAVP) treatment.
Number of subjects: 32
Study: 34420970

Group type: EXPERIMENTAL
Intervention: BetterBrains intervention (online person-centered risk factor management program)
Number of subjects: 1510

Group type: COMPARATOR
Intervention: Psychoeducational health information (provided to both groups)
Number of subjects: 1510
Study: 32394228

Group type: EXPERIMENTAL
Intervention: Lixisenatide (20 μg single-dose injection)
Number of subjects: 24